Table 1.
Gene (G-band) | Probe Design | Myeloid leukemia | Lymphocytic leukemia | Lymphoma | MM/MGUS | MPD | ||||
---|---|---|---|---|---|---|---|---|---|---|
CML | MDS | AML | CLL | B-ALL | T-ALL | |||||
CKS1B (1q21), CDKN2C (1p32) | DCE | 1p/1q+ | ||||||||
PBX1 (1q23.3), TCF3 (19p13.3) | DCDF | t(1;19) | t(1;19) | |||||||
ALK (2p23) | DCBAP | ALK | ||||||||
MECOM (3q26) | DCBAP | inv(3) | ||||||||
BCL6 (3q27) | DCBAP | BCL6 | ||||||||
D4Z1 (4cen), D10Z1 (10cen), D17Z1 (17cen) | TCE | +4/10/17 | ||||||||
PDGFRA (4q12) | DCBAP | PDGFRA | ||||||||
FGFR3 (4p16.3), IGH (14q32) | DCDF | t(4;14) | ||||||||
TAS2R1 (5p15.31), EGR1 (5q31) | DCE | 5q−/−5 | ||||||||
PDGFRB (5q33) | DCBAP | PDGFRB | PDGFRB | |||||||
MYB (6q23), D6Z1 (6cen) | DCE | 6q− | ||||||||
RELN (7q22), TES (7q31) | DCE | 7q−/−7 | ||||||||
TCRB (7q34) | DCBAP | TCRB | ||||||||
FGFR1 (8p11) | DCBAP | FGFR1 | ||||||||
RUNX1T1 (8q21), RUNX1 (21q22) | DCDF | t(8;21) | ||||||||
cMYC (8q24) | DCBAP | cMYC | ||||||||
cMYC (8q24), D20S108 (20q12) | DCE | +8/20q− | ||||||||
PAX5 (9p13.2) | DCBAP | PAX5 | ||||||||
CDKN2A (9p21), D9Z3 (9cen) | DCE | 9p− | 9p− | |||||||
ABL (9q34), BCR (22q11) | DCDF | t(9;22) | t(9;22) | t(9;22) | ||||||
CCND1 (11q13), IGH (14q32) | DCDF | t(11;14) | t(11;14) | |||||||
ATM (11q22), TP53 (17p13) | DCE | 11q−/17p− | ||||||||
KMT2A (11q23) | DCBAP | KMT2A | KMT2A | KMT2A | ||||||
ETV6 (12p13), RUNX1 (21q22) | DCDF | t(12;21) | ||||||||
DLEU1 (13q14), D13S25 (13q34) | DCE | 13q− | ||||||||
DLEU1 (13q14), D13S25 (13q34), D12Z3 (12cen) | TCE | 13q−/+12 | ||||||||
TCRA/D (14q11) | DCE | TCRA | ||||||||
IGH (14q32) | DCBAP | IGH | IGH | IGH | ||||||
IGH (14q32), BCL2 (18q21) | DCDF | t(14;18) | ||||||||
SNRPN (15q11.2), TP53 (17p13) | DCE | +15/17p− | ||||||||
PML (15q24), RARA (17q21) | DCDF | t(15;17) | ||||||||
MYH11 (16p13), CBFB (16q22) | DCDF | inv(16) | ||||||||
MALT1 (18q21) | DCBAP | MALT1 | ||||||||
CRLF2 (Xp22.33) | DCBAP | CLFR2 |
DCE,dual-color enumerate; TCE, tri-color enumerate; DCBAP, dual-color break apart; DCDF, dual-color double fusion; CML, Chronic myeloid leukemia; MDS, Myelodysplastic syndrome; AML, Acute myeloid leukemia; CLL, Chronic lymphocytic leukemia; B-ALL, B-cell acute lymphocytic leukemia; T-ALL, T-cell acute lymphocytic leukemia; MM/MGUS, Multiple myeloma/Monoclonal mopathy of undetermined significance; MPD, Myeloproliferative disorder. Shaded for recurrent abnormalities detected by a primary FISH panel, unshaded for secondary FISH probes for specific abnormalities. For references see (Hu et al., 2014; Liehr et al., 2015), and (Mikhail et al., 2016).